HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PODD

Insulet Corporation (NASDAQ)

Healthcare — Medical Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Strong Buy 1.4 / 5 24 analysts
$159.79
+$7.54 (+4.95%)
Target: $240.25 (50.4%)
Sign in to add PODD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$11.07B
P/E Ratio (TTM)37.33
Forward P/E19.77
EPS (TTM)$4.28
Dividend Yield-
Profit Margin10.44%
Revenue Growth33.90%
ROE23.00%
Debt/Equity77.84
Recommendation Strong Buy 1.4
Analyst Target$240.25
Analysts24
Indexes NASDAQ

Technical Indicators

RSI (14)59.1
Beta1.13
SMA 20-
SMA 40-
52-Week High$354.88
52-Week Low$138.79
50-Day Avg$157.28
200-Day Avg$248.70
Avg Volume$1.50M
Volume$1.52M

Performance Analysis

BULLISH

PODD shows predominantly bullish signals based on its fundamentals and technicals.

+ Trading near its 52-week low ($138.79), which could present a value opportunity.
+ RSI at 59.1 shows positive momentum.
+ Strong revenue growth of 33.9% year-over-year.
+ Wall Street consensus is "Strong Buy" from 24 analysts.
+ Average analyst target of $240.25 implies 50.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:27 UTC

Back to Screener Export Report